Cargando…
Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
Recombinant human interleukin‐2 (rIL‐2) was administered to 34 patients with advanced malignancy. Three schedules of rIL‐2 administration employed were as follows: (A) 2‐hr iv infusion of 6.7 × 10(*5) U/m(*2)/day (A(1), 6 cases) or 2.2 × 10(*6) U/m(*2)/day (A(2), 8 cases) for five consecutive days;...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
1988
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907760/ https://www.ncbi.nlm.nih.gov/pubmed/3128501 http://dx.doi.org/10.1111/j.1349-7006.1988.tb00020.x |